Sarfraz Memon
Overview
Explore the profile of Sarfraz Memon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holtzman N, Curtis L, Salit R, Shaffer B, Pirsl F, Ostojic A, et al.
Blood Adv
. 2024 Apr;
8(16):4294-4310.
PMID: 38669315
Chronic graft-versus-host disease (cGVHD) remains a significant problem for patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although in vivo lymphodepletion for cGVHD prophylaxis has been explored in the myeloablative...
2.
Goklemez S, Hasni S, Hakim F, Muraro P, Pirsl F, Rose J, et al.
Rheumatology (Oxford)
. 2021 Dec;
61(8):3317-3328.
PMID: 34875023
Objective: Autologous haematopoietic cell transplantation (AHSCT) improves immunologic dysfunction in patients with SLE. However, the curative potential of this therapy remains uncertain. This study reports outcomes in SLE patients receiving...
3.
Hakim F, Memon S, Jin P, Imanguli M, Wang H, Rehman N, et al.
J Immunol
. 2016 Oct;
197(9):3490-3503.
PMID: 27694491
Although chronic graft-versus-host disease (CGVHD) is the primary nonrelapse complication of allogeneic transplantation, understanding of its pathogenesis is limited. To identify the main operant pathways across the spectrum of CGVHD,...
4.
Odeh H, Miranda L, Rao A, Vaught J, Greenman H, McLean J, et al.
Biopreserv Biobank
. 2015 Dec;
13(6):421-9.
PMID: 26697911
Background: Biospecimens are essential resources for advancing basic and translational research. However, there are little data available regarding the costs associated with operating a biobank, and few resources to enable...
5.
Hardy N, Fellowes V, Rose J, Odom J, Pittaluga S, Steinberg S, et al.
Blood
. 2012 Feb;
119(12):2956-9.
PMID: 22289893
Donor lymphocyte infusion (DLI), a standard relapse treatment after allogeneic stem cell transplantation (AlloSCT), has limited efficacy and often triggers GVHD. We hypothesized that after AlloSCT tumor-infiltrating donor lymphocytes could...
6.
Le R, Melenhorst J, Battiwalla M, Hill B, Memon S, Savani B, et al.
Blood
. 2011 Mar;
117(19):5250-6.
PMID: 21421838
After allogeneic stem cell transplantation (SCT), T lymphocyte function is reestablished from the donor's postthymic T cells and through thymic T-cell neogenesis. The immune repertoire and its relation to that...
7.
Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski M, Vance B, et al.
Biol Blood Marrow Transplant
. 2008 Feb;
14(3):290-300.
PMID: 18275895
Because natural killer (NK) cells can be potent anti-tumor effectors after allogeneic stem cell transplantation, we investigated NK reconstitution and receptor expression in patients undergoing allogeneic hematopoietic stem cell transplantation,...
8.
Lan Q, Zhang L, Hakim F, Shen M, Memon S, Li G, et al.
Chem Biol Interact
. 2005 Jun;
153-154:111-5.
PMID: 15935806
We have previously reported that benzene decreases peripheral white blood cell and platelet counts and specifically lowers subsets of several blood cell types, including CD4+-T cells, B cells, NK cells,...
9.
Muraro P, Douek D, Packer A, Chung K, Guenaga F, Cassiani-Ingoni R, et al.
J Exp Med
. 2005 Mar;
201(5):805-16.
PMID: 15738052
Clinical trials have indicated that autologous hematopoietic stem cell transplantation (HSCT) can persistently suppress inflammatory disease activity in a subset of patients with severe multiple sclerosis (MS), but the mechanism...